Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial

Endotracheal intubation is a procedure that may cause significant hemodynamic perturbations and can severely impact the outcome of the critically ill. To ensure a safe outcome during this particular procedure, there are many factors that the clinician is faced with. One decision that confronts the critical care physician involves the correct combination of medications with which to facilitate such a safe outcome. Given the reported hemodynamic stability, etomidate is a medication that is chosen by many providers in this particular situation. However, its association with a possible increase in mortality makes it less than ideal for a number of critical care physicians. In recent years, an admixture of propofol and ketamine has been studied that demonstrates hemodynamic stability based on the balancing of the hemodynamic effects of these two individual agents alone. This novel medication combination, sometimes referred to as "ketofol", may offer a valuable alternative to the critical care physician. Therefore, a randomized parallel-group clinical trial of adult critically ill patients admitted to a medical and/or surgical intensive care unit at Mayo Clinic Rochester who meet the criteria designated below for which urgent and/or emergent intubation is needed will receive one of two interventions based on stratified randomization. The "active" intervention arm will receive ketamine/propofol (ketofol) to facilitate endotracheal intubation. The comparison arm will receive etomidate. The primary outcome will focus on hemodynamic data recorded during the first 5 minutes post-administration with secondary outcomes looking at hemodynamic data at 10 and 15 minutes and addressing intensive care unit length of stay, mortality, adrenal function, and vasoactive medication use, among others.

Inclusion criteria

• 18 years of age or older
• Surgical or medical intensive care unity patients requiring endotracheal intubation
• Consulting physician agrees to study plan and will follow drug randomization

Exclusion criteria

• Known intracranial pathology
• Known chronic opiate-dependence
• Received continuous sedative infusion in the last 24 hours
• Known severe psychiatric illness
• Known egg allergies
• Known contraindication to fentanyl, midazolam, ketamine, propofol or etomidate
• Intubation in which standard practice is not to use sedation
• No known documented weight or weight greater than 140 kg or less than 30 kg
• Prior participation in the study
• Of childbearing age (18-50) with no known negative pregnancy test on this admission.